Pivagabine
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Pivagabine
- DrugBank Accession Number
- DB12951
- Background
Pivagabine has been used in trials studying the treatment of Stress and Anxiety.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 187.239
Monoisotopic: 187.120843411 - Chemical Formula
- C9H17NO3
- Synonyms
- 4-Pivalamidobutyric acid
- Pivagabina
- Pivagabine
- Pivagabinum
- External IDs
- CXB-722
- CXB722
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Pivagabine. Acenocoumarol The risk or severity of adverse effects can be increased when Pivagabine is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Pivagabine. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Pivagabine. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Pivagabine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Tonerg
Categories
- ATC Codes
- N06AX15 — Pivagabine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Gamma amino acids and derivatives
- Alternative Parents
- Branched fatty acids / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Branched fatty acid / Carbonyl group / Carboxamide group / Carboxylic acid / Fatty acid / Fatty acyl / Gamma amino acid or derivatives / Hydrocarbon derivative / Monocarboxylic acid or derivatives
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C53SV0WO4V
- CAS number
- 69542-93-4
- InChI Key
- SRPNQDXRVRCTNK-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H17NO3/c1-9(2,3)8(13)10-6-4-5-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12)
- IUPAC Name
- 4-(2,2-dimethylpropanamido)butanoic acid
- SMILES
- CC(C)(C)C(=O)NCCCC(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 68888
- PubChem Substance
- 347829093
- ChemSpider
- 62118
- ChEBI
- 134834
- ChEMBL
- CHEMBL1870796
- ZINC
- ZINC000001545856
- Wikipedia
- Pivagabine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Completed Treatment Anxiety / Stress (Psychology) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 4.14 mg/mL ALOGPS logP 1.07 ALOGPS logP 1 Chemaxon logS -1.7 ALOGPS pKa (Strongest Acidic) 4.75 Chemaxon pKa (Strongest Basic) -0.86 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 66.4 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 48.6 m3·mol-1 Chemaxon Polarizability 20.5 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9700000000-f1a50d9b416361c2c6a0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udr-2900000000-8824b4254cb58afe5a0d Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9100000000-3d1b94156b77ff1c5b5c Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-7900000000-24aae2bc0d041513d488 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-052f-9000000000-6639be996df8fa563811 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9000000000-f8de47f2750d67a0ead5 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 146.6665124 predictedDarkChem Lite v0.1.0 [M-H]- 140.4209 predictedDeepCCS 1.0 (2019) [M+H]+ 148.2719124 predictedDarkChem Lite v0.1.0 [M+H]+ 144.24825 predictedDeepCCS 1.0 (2019) [M+Na]+ 147.7514124 predictedDarkChem Lite v0.1.0 [M+Na]+ 153.13042 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 01:33 / Updated at June 28, 2022 01:51